Download PDF
Deutsche Zeitschrift für Onkologie 2020; 52(03): 117-123
DOI: 10.1055/a-1234-4402
Forschung

Mikronährstoffe in der Onkologie: Risiko und Nutzen

Update 2020
Ralph Mücke
1   Strahlentherapie RheinMainNahe, Standort Bad Kreuznach
2   Klinik für Strahlentherapie und Radioonkologie, Ruhr-Universität Bochum
,
Oliver Micke
3   Klinik für Strahlentherapie und Radioonkologie, Franziskus-Hospital Bielefeld
,
Jens Büntzel
4   Klinik für HNO-Heilkunde, Südharzklinikum Nordhausen
,
Irenaeus A. Adamietz
2   Klinik für Strahlentherapie und Radioonkologie, Ruhr-Universität Bochum
,
Khashayar Fakhrian
2   Klinik für Strahlentherapie und Radioonkologie, Ruhr-Universität Bochum
› Author Affiliations
› Further Information
    Permissions and Reprints

Zusammenfassung

Hintergrund Das Interesse sowohl von betreuenden Ärzten als auch Tumorpatienten an der zusätzlichen Einnahme von Mikronährstoffen während einer onkologischen Therapie mit unterschiedlichen Intentionen nimmt zu. Dieses Update liefert deshalb eine Standortbestimmung zum zusätzlichen Einsatz von ausgewählten Mikronährstoffen während der Tumortherapie.

Methoden Es wurde eine Literaturrecherche hinsichtlich des Einsatzes von ausgewählten Mikronährstoffen in der Onkologie, die bis 2018 in zitierfähigen Journalen erschienen sind, durchgeführt.

Ergebnisse Daten zu Mikronährstoffen, die sowohl hinsichtlich der Lebensqualität als auch der Prognose einen Nutzen für onkologische Patienten bringen, als auch Erkenntnisse zu Mikronährstoffen, die für die Patienten keinen Benefit haben oder sogar schaden, werden präsentiert. Die gute Datenlage hinsichtlich Vitamin D und Selen erlaubt hier die Empfehlung zur Supplementation nach Spiegelbestimmung im Serum.

Schlussfolgerung Nicht nur vorrangig onkologisch tätige Ärzte, sondern auch alle Ärzte, die Tumorpatienten mitbetreuen, sollten Kenntnisse über die wichtigsten Mikronährstoffe haben, um diese an die Patienten weiterzugeben und sie auch gezielt zum Nutzen der Patienten einzusetzen.

Zusatzmaterial



Publication History

Article published online:
24 September 2020

© 2020. Thieme. All rights reserved.

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Neuhouser ML, Cheng TY, Beresford SA. et al. Red blood cell folate and plasma folate are not associated with risk of incident colorectal cancer in the Women's Health Initiative observational study. Int J Cancer 2015; 137: 930-939
    CrossrefPubMedGoogle Scholar
  • 2 Mortensen JH, Øyen N, Fomina T. et al. Supplemental folic acid in pregnancy and childhood cancer risk. Br J Cancer 2016; 114: 71-75
    CrossrefPubMedGoogle Scholar
  • 3 Mortensen JH, Øyen N, Fomina T. et al. Supplemental folic acid in pregnancy and maternal cancer risk. Cancer Epidemiol 2015; 39: 805-811
    CrossrefPubMedGoogle Scholar
  • 4 Taylor CM, Atkinson C, Penfold C. et al. Folic acid in pregnancy and mortality from cancer and cardiovascular disease: further follow-up of the Aberdeen folic acid supplementation trial. J Epidemiol Community Health 2015; 69: 789-794
    CrossrefPubMedGoogle Scholar
  • 5 Qin T, Du M, Du H. et al. Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials. Sci Rep 2015; 5: 12044
    CrossrefPubMedGoogle Scholar
  • 6 Burr NE, Hull MA, Subramanian V. Folic acid supplementation may reduce colorectal cancer risk in patients with inflammatory bowel disease: A systematic review and meta-analysis. J Clin Gastroenterol 2017; 51: 247-253
    CrossrefPubMedGoogle Scholar
  • 7 Moazzen S, Dolatkhah R, Tabrizi JS. et al. Folic acid intake and folate status and colorectal cancer risk: A systematic review and meta-analysis. Clin Nutr 2018; 37: 1926-1934
    CrossrefPubMedGoogle Scholar
  • 8 Wien TN, Pike E, Wisløff T. et al. Cancer risk with folic acid supplements: A systematic review and meta-analysis. BMJ Open 2012; 2 (01) e000653
    CrossrefPubMedGoogle Scholar
  • 9 Fan C, Yu S, Zhang S. et al. Association between folate intake and risk of head and neck squamous cell carcinoma: An overall and dose-response PRISMA meta-analysis. Medicine (Baltimore) 2017; 96 (42) e8182
    CrossrefPubMedGoogle Scholar
  • 10 Kawakita D, Lee YA, Gren LH. et al. The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. Br J Cancer 2018; 118: 299-306
    CrossrefPubMedGoogle Scholar
  • 11 Fanidi A, Muller DC, Yuan JM. et al. Circulating folate, vitamin B6, and methionine in relation to lung cancer risk in the Lung Cancer Cohort Consortium (LC3). J Natl Cancer Inst 2018; 110: 57-67
    CrossrefPubMedGoogle Scholar
  • 12 Kraft M, Kraft K, Gärtner S. et al. L-Carnitine supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial. Nutr J 2012; 11: 52
    CrossrefPubMedGoogle Scholar
  • 13 Mücke M, Mochamat Cuhls H. et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2015; 30: CD006788
    PubMedGoogle Scholar
  • 14 Marx W, Teleni L, Opie RS. et al. Efficacy and effectiveness of carnitine supplementation for cancer-related fatigue: A systematic literature review and meta-analysis. Nutrients 2017; 9: E1224
    CrossrefPubMedGoogle Scholar
  • 15 Hershman DL, Unger JM, Crew KD. et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013; 31: 2627-2633
    CrossrefPubMedGoogle Scholar
  • 16 Armenian SH, Gelehrter SK, Vase T. et al. Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. Cancer Epidemiol Biomarkers Prev 2014; 23: 1109-1114
    CrossrefPubMedGoogle Scholar
  • 17 Bakker MF, Peeters PH, Klaasen VM. et al. Plasma carotenoids, vitamin C, tocopherols, and retinol and the risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr 2016; 103: 454-464
    CrossrefPubMedGoogle Scholar
  • 18 Leoncini E, Edefonti V, Hashibe M. et al. Carotenoid intake and head and neck cancer: a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Eur J Epidemiol 2016; 31: 369-383
    CrossrefPubMedGoogle Scholar
  • 19 Nordström T, Van Blarigan EL, Ngo V. et al. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 2016; 76: 339-348
    CrossrefPubMedGoogle Scholar
  • 20 Yu N, Su X, Wang Z. et al. Association of dietary vitamin A and β-carotene intake with the risk of lung cancer: A meta-analysis of 19 publications. Nutrients 2015; 7: 9309-9324
    CrossrefPubMedGoogle Scholar
  • 21 Margalit DN, Kasperzyk JL, Martin NE. et al. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study. J Radiat Oncol Biol Phys 2012; 83: 28-32
    CrossrefPubMedGoogle Scholar
  • 22 De Munter L, Maasland DH, van den Brandt PA. et al. Vitamin and carotenoid intake and risk of head-neck cancer subtypes in the Netherlands Cohort Study. Am J Clin Nutr 2015; 102: 420-432
    CrossrefPubMedGoogle Scholar
  • 23 Edefonti V, Hashibe M, Parpinel M. et al. Natural vitamin C intake and the risk of head and neck cancer: A pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer 2015; 137: 448-462
    CrossrefPubMedGoogle Scholar
  • 24 Bo Y, Lu Y, Zhao Y. et al. Association between dietary vitamin C intake and risk of esophageal cancer: A dose-response meta-analysis. Int J Cancer 2015; 138: 1843-1850
    CrossrefPubMedGoogle Scholar
  • 25 Fan H, Kou J, Han D. et al. Association between vitamin C intake and the risk of pancreatic cancer: a meta-analysis of observational studies. Sci Rep 2015; 5: 13973
    CrossrefPubMedGoogle Scholar
  • 26 Bai XY, Qu X, Jiang X. et al. Association between dietary vitamin C intake and risk of prostate cancer: A meta-analysis involving 103,658 subjects. J Cancer 2015; 6: 913-921
    CrossrefPubMedGoogle Scholar
  • 27 Shareck M, Rousseau MC, Koushik A. et al. Inverse association between dietary intake of selected carotenoids and vitamin C and risk of lung cancer. Front Oncol 2017; 7: 23
    CrossrefPubMedGoogle Scholar
  • 28 Narita S, Saito E, Sawada N. et al. Dietary consumption of antioxidant vitamins and subsequent lung cancer risk: The Japan Public Health Center-based prospective study. Int J Cancer 2018; 142: 2441-2460
    CrossrefPubMedGoogle Scholar
  • 29 Cao D, Shen K, Li Z. et al. Association between vitamin C Intake and the risk of cervical neoplasia: A meta-analysis. Nutr Cancer 2016; 68: 48-57
    CrossrefPubMedGoogle Scholar
  • 30 Harris HR, Bergkvist L, Wolk A. Vitamin C intake and breast cancer mortality in a cohort of Swedish women. Br J Cancer 2013; 109: 257-264
    CrossrefPubMedGoogle Scholar
  • 31 Harris HR, Orsini N, Wolk A. Vitamin C and survival among women with breast cancer: a meta-analysis. Eur J Cancer 2014; 50: 1223-1231
    CrossrefPubMedGoogle Scholar
  • 32 Poole EM, Shu X, Caan BJ. et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2013; 139: 529-537
    CrossrefPubMedGoogle Scholar
  • 33 Tsinovoi CL, Xun P, He K. Antioxidant supplementation is not associated with long-term quality of life in stage-II colorectal cancer survivors: A follow-up of the Study of Colorectal Cancer Survivors Cohort. Nutrition and cancer 2017; 69: 159-166
    CrossrefPubMedGoogle Scholar
  • 34 Jacobs C, Hutton B, Ng T, Shorr R. et al. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist 2015; 20: 210-223
    CrossrefPubMedGoogle Scholar
  • 35 Heaney ML, Gardner JR, Karasavvas N. et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008; 68: 8031-8038
    CrossrefPubMedGoogle Scholar
  • 36 Llobet D, Eritja N, Encinas M. et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008; 19: 115-124
    CrossrefPubMedGoogle Scholar
  • 37 Perrone G, Hideshima T, Ikeda H. et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009; 23: 1679-1686
    CrossrefPubMedGoogle Scholar
  • 38 Campbell GD, Steinberg MH, Bower JD. Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 1975; 82: 810
    CrossrefPubMedGoogle Scholar
  • 39 Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ (Clinical Research ed.) 1993; 306: 841-842
    CrossrefPubMedGoogle Scholar
  • 40 Pilz S, Kienreich K, Tomaschitz A. et al. Vitamin D and cancer mortality: Systematic review of prospective epidemiological Studies. Anticancer Agents Med Chem 2013; 13: 107-117
    CrossrefPubMedGoogle Scholar
  • 41 Raimondi S, Johansson H, Maisonneuve P. et al. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009; 30: 1170-1180
    CrossrefPubMedGoogle Scholar
  • 42 McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009; 29: 111-132
    CrossrefPubMedGoogle Scholar
  • 43 Yin L, Ordóñez-Mena JM, Chen T. et al. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. Prev Med 2013; 57: 753-764
    CrossrefPubMedGoogle Scholar
  • 44 Ma Y, Zhang P, Wang F. et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011; 29: 3775-3782
    CrossrefPubMedGoogle Scholar
  • 45 Yin L, Grandi N, Raum E. et al. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30: 113-125
    CrossrefPubMedGoogle Scholar
  • 46 Zhang L, Wang S, Che X. et al. Vitamin D and lung cancer risk: A comprehensive review and meta-analysis. Cell Physiol Biochem 2015; 36: 299-305
    CrossrefPubMedGoogle Scholar
  • 47 Stanaland M, Jiroutek MR, Holland MA. Study of the association between serum vitamin D levels and prostate cancer. Military Med 2017; 182: e1769-e1774
    CrossrefPubMedGoogle Scholar
  • 48 O'Brien KM, Sandler DP, Taylor JA. et al. Serum vitamin D and risk of breast cancer within five years. Environ Health Perspect 2017; 125: 077004
    CrossrefPubMedGoogle Scholar
  • 49 Andersen SW, Shu XO, Cai Q. et al. Total and free circulating vitamin D and vitamin D-binding protein in relation to colorectal cancer risk in a prospective study of African Americans. Cancer Epidemiol Biomarkers Prev 2017; 26: 1242-1247
    CrossrefPubMedGoogle Scholar
  • 50 Ekmekcioglu C, Haluza D, Kundi M. 25-Hydroxyvitamin D status and risk for colorectal cancer and type 2 diabetes mellitus: A systematic review and meta-analysis of epidemiological studies. Int J Environ Res Public Health 2017; 14: E127
    CrossrefPubMedGoogle Scholar
  • 51 Garland CF, Gorham ED. Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: A meta-analysis. J Steroid Biochem Mol Biol 2017; 168: 1-8
    CrossrefPubMedGoogle Scholar
  • 52 Ammann EM, Drake MT, Haraldsson B. et al. Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation. Cancer 2017; 123: 4168-4177
    CrossrefPubMedGoogle Scholar
  • 53 de Gruijl FR, Wolterbeek R, Pavel S. et al. Low wintertime pre-diagnostic vitamin D status is associated with an increased risk of internal malignancies in kidney transplant recipients. Photochem Photobiol Sci 2018; 17: 1946-1955
    CrossrefPubMedGoogle Scholar
  • 54 Fedirko V, Riboli E, Tjønneland A. et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in Western European populations. Cancer Epidemiol Biomarkers Prev 2012; 21: 582-593
    CrossrefPubMedGoogle Scholar
  • 55 Goodwin PJ, Ennis M, Pritchard KI. et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-3763
    CrossrefPubMedGoogle Scholar
  • 56 Maalmi H, Ordóñez-Mena JM, Schöttker B. et al. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur J Cancer 2014; 50: 1510-1521
    CrossrefPubMedGoogle Scholar
  • 57 Mohr SB, Gorham ED, Kim J. et al. Could vitamin D sufficiency improve the survival of colorectal cancer patients?. J Steroid Biochem Mol Biol 2015; 148: 239-244
    CrossrefPubMedGoogle Scholar
  • 58 Pilz S, Kienreich K, Tomaschitz A. et al. Vitamin D and cancer mortality: systematic review of prospective epidemiological studies. Anticancer Agents Med Chem 2013; 13: 107-117
    CrossrefPubMedGoogle Scholar
  • 59 Poole EM, Shu X, Caan BJ. et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2013; 139: 529-537
    CrossrefPubMedGoogle Scholar
  • 60 Villaseñor A, Ballard-Barbash R, Ambs A. et al. Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. Cancer Causes Control 2013; 24: 759-767
    CrossrefPubMedGoogle Scholar
  • 61 Vrieling A, Hein R, Abbas S. et al. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 2011; 13: R74
    CrossrefPubMedGoogle Scholar
  • 62 Zgaga L, Theodoratou E, Farrington SM. et al. Plasma vitamin D concentration influences survival outcome after diagnosis of colorectal cancer. J Clin Oncol 2014; 32: 2430-2439
    CrossrefPubMedGoogle Scholar
  • 63 Hu K, Callen DF, Li J. et al. Circulating vitamin D and overall survival in breast cancer patients: A dose-response meta-analysis of cohort studies. Integr Cancer Ther 2018; 17: 217-225
    CrossrefPubMedGoogle Scholar
  • 64 Yao S, Kwan ML, Ergas IJ. et al. Association of serum level of vitamin D at diagnosis with breast cancer survival: A case-cohort analysis in the Pathways Study. JAMA Oncol 2017; 3: 351-357
    CrossrefPubMedGoogle Scholar
  • 65 Huang JD, Dong CH, Shao SW. et al. Circulating 25-hydroxyvitamin D level and prognosis of lung cancer patients: A systematic review and meta-analysis. Bull Cancer 2017; 104: 675-682
    CrossrefPubMedGoogle Scholar
  • 66 Maalmi H, Walter V, Jansen L. et al. Relationship of very low serum 25-hydroxyvitamin D3 levels with long-term survival in a large cohort of colorectal cancer patients from Germany. Eur J Epidemiol 2017; 32: 961-971
    CrossrefPubMedGoogle Scholar
  • 67 Bittenbring JT, Neumann F, Altmann B. et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcomeof patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32: 3242-3248
    CrossrefPubMedGoogle Scholar
  • 68 Tracy SI, Maurer MJ, Witzig TE. et al. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J 2017; 7: e595
    CrossrefPubMedGoogle Scholar
  • 69 Hohaus S, Tisi MC, Bellesi S. et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med 2018; 7: 270-281
    CrossrefPubMedGoogle Scholar
  • 70 Timerman D, McEnery-Stonelake M, Joyce CJ. et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8: 6873-6882
    CrossrefPubMedGoogle Scholar
  • 71 Weinstein SJ, Mondul AM, Yu K. et al. Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival. Eur J Epidemiol 2018; 33: 1087-1099
    CrossrefPubMedGoogle Scholar
  • 72 Yokosawa EB, Arthur AE, Rentschler KM. et al. Vitamin D intake and survival and recurrence in head and neck cancer patients. The Laryngoscope 2018; 128: e371-e376
    CrossrefPubMedGoogle Scholar
  • 73 Gilbert R, Martin RM, Fraser WD. et al. Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes Control 2012; 23: 575-588
    CrossrefPubMedGoogle Scholar
  • 74 Rastelli AL, Taylor ME, Gao F. et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 2011; 129: 107-116
    CrossrefPubMedGoogle Scholar
  • 75 Hoffmann MR, Senior PA, Mager DR. Vitamin D supplementation and health-related quality of life: a systematic review of the literature. J Acad Nutr Diet 2015; 115: 406-418
    CrossrefPubMedGoogle Scholar
  • 76 Mücke R, Schomburg L, Büntzel J. et al. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe 2010; 16: 181-186
    CrossrefPubMedGoogle Scholar
  • 77 Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 2008; 168: 404-410
    CrossrefPubMedGoogle Scholar
  • 78 Cai X, Wang C, Yu W. et al. Selenium exposure and cancer risk: an updated meta-analysis and meta-regression. Sci Rep 2016; 6: 19213
    CrossrefPubMedGoogle Scholar
  • 79 Vinceti M, Filippini T, Del Giovane C. et al. Selenium for preventing cancer. Cochrane Database Syst Rev 2018; 1: Cd005195
    PubMedGoogle Scholar
  • 80 Lippman SM, Klein EA, Goodman PJ. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009; 301: 39-51
    CrossrefPubMedGoogle Scholar
  • 81 Mücke R, Schomburg L, Büntzel J. et al. German Working Group Trace Elements and Electrolytes in Oncology. Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther 2010; 9: 136-141
    CrossrefPubMedGoogle Scholar
  • 82 Geybels MS, Verhage BA, van Schooten FJ. et al. Advanced prostate cancer risk in relation to toenail selenium Levels. J Natl Cancer Inst 2013; 105: 1394-1401
    CrossrefPubMedGoogle Scholar
  • 83 Kristal AR, Darke AK, Morris JS. et al. Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. J Natl Cancer Inst 2014; 106: djt456
    CrossrefPubMedGoogle Scholar